Related Experiment Video
Updated: Nov 18, 2025

Anesthesia and Intubation of Preadolescent Mouse Pups for Cardiothoracic Surgery
Published on: June 2, 2022
Dexmedetomidine and Iatrogenic Withdrawal Syndrome in Critically Ill Children
Barbara M Geven1, Jolanda M Maaskant2, Catherine S Ward3
1Barbara M. Geven is a pediatric intensive care nurse and clinical epidemiologist, Amsterdam UMC/Emma Children's Hospital, University of Amsterdam, Amsterdam, the Netherlands.
Insights
Supplemental dexmedetomidine did not prevent iatrogenic withdrawal syndrome in pediatric intensive care unit patients on mechanical ventilation. Higher midazolam doses were linked to increased withdrawal symptoms.
Area of Science:
- Pediatric Intensive Care
- Pharmacology
- Critical Care Medicine
Background:
- Iatrogenic withdrawal syndrome (IWS) is a common adverse effect in pediatric patients on mechanical ventilation, with incidence up to 64.6%.
- Standard sedatives and analgesics may be insufficient, leading to the use of supplemental dexmedetomidine.
- The impact of dexmedetomidine on IWS in this population remains unclear.
Purpose of the Study:
- To investigate the potential preventive effect of dexmedetomidine on IWS.
- To assess dexmedetomidine as an adjunct to standard morphine and midazolam regimens.
- To evaluate IWS development in mechanically ventilated pediatric intensive care unit patients.
Main Methods:
- Retrospective observational study in a 10-bed general pediatric intensive care unit.
- Data collected from 102 patients receiving mechanical ventilation.
- Iatrogenic withdrawal syndrome assessed using the Sophia Observation withdrawal Symptoms-scale.
Main Results:
- Cumulative dexmedetomidine dose showed no preventive effect on IWS (P = .19).
- After adjusting for baseline characteristics, cumulative midazolam dose was a significant risk factor for IWS (P < .03).
Conclusions:
- Supplemental dexmedetomidine does not appear to prevent IWS in pediatric ICU patients.
- Midazolam cumulative dose is identified as a significant risk factor for developing IWS.
- Further research may be needed to identify effective strategies for preventing IWS.
Background:
Iatrogenic withdrawal syndrome is a well-known adverse effect of sedatives and analgesics commonly used in patients receiving mechanical ventilation in the pediatric intensive care unit, with an incidence of up to 64.6%. When standard sedative and analgesic treatment is inadequate, dexmedetomidine may be added. The effect of supplemental dexmedetomidine on iatrogenic withdrawal syndrome is unclear.
Objective:
To explore the potentially preventive effect of dexmedetomidine, used as a supplement to standard morphine and midazolam regimens, on the development of iatrogenic withdrawal syndrome in patients receiving mechanical ventilation in the pediatric intensive care unit.
Methods:
This retrospective observational study used data from patients on a 10-bed general pediatric intensive care unit. Iatrogenic withdrawal syndrome was measured using the Sophia Observation withdrawal Symptoms-scale.
Results:
In a sample of 102 patients, the cumulative dose of dexmedetomidine had no preventive effect on the development of iatrogenic withdrawal syndrome (P = .19). After correction for the imbalance in the baseline characteristics between patients who did and did not receive dexmedetomidine, the cumulative dose of midazolam was found to be a significant risk factor for iatrogenic withdrawal syndrome (P < .03).
Conclusion:
In this study, supplemental dexmedetomidine had no preventive effect on iatrogenic withdrawal syndrome in patients receiving sedative treatment in the pediatric intensive care unit. The cumulative dose of midazolam was a significant risk factor for iatrogenic withdrawal syndrome.
Related Concept Videos
Parenteral Anesthetics: Overview
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Depolarizing Blockers: Pharmocokinetics
Pharmacokinetics in Pediatric Patients: Drug Excretion
Stages of General Anesthesia

